Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3368-3377

  Trovik, Jone ^a,b   Wik, Elisabeth ^b   Stefansson, Ingunn M ^a,b   Marcickiewicz, Janusz ^c   Tingulstad, Solveig ^d   Staff, Anne C ^e,f   Njolstad, Tormund S ^b   Vandenput, Ingrid ^l   Amant, Frederic ^l   Akslen, Lars A ^a,b   Salvesen, Helga B ^a,b   Engh, M E ^g   Oddenes, K ^h   Rokne, J A ⁱ   Jugum, J T ^j   Lode, M S ^k  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^h HAUGESUND HOSPITAL   (Norway)

ⁱ VESTFOLD HOSPITAL TRUST   (Norway)

^j Foerde Central Hospital   (Norway)

^k Aalesund Hospital   (Norway)

^l UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

STATHMIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; STATHMIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79956000555     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2412     Document Type: Article

References (45)

1. Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer 2005;117:123-31. (Pubitemid 41262766)
2. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
3. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67:3093-103.
4. Cancer in Norway 2008. Report. Oslo: Cancer Registry of Norway; 2009.
5. Panici PB, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
6. ASTEC study group Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. The Lancet 2009; 373:125-36.
7. Rubin CI, Atweh GF The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004;93:242-50. (Pubitemid 44264202)
8. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002;62:6864-9. (Pubitemid 35424074)
9. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009;106:4834-9.
10. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104:7564-9. (Pubitemid 47185946)
11. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000;83:311-8. (Pubitemid 30453569)
12. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009;115:2453-63.
13. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 2009;135:837-46.
14. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006;441:424-30. (Pubitemid 44050136)
15. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008;1784:150-8.
16. Engelman JA. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
17. ClinicalTrials.gov. [Web Page] Bethesda, MD: NIH; January Molecular Markers in Treatment in Endometrial Cancer, NCT00598845.11, 2010 [updated 2010 Jan 11; cited 2010 Dec 20]. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00598845.
18. FIGO (International Federation of Gynecology and Obstetrics). FIGO news. Corpus cancer staging. Int J Gynecol Obstet 1989;28:189-90.
19. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-52. (Pubitemid 41079838)
20. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7. (Pubitemid 28331029)
21. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol 2008;18:89-97. (Pubitemid 351296453)
22. Proteinatlas.org. [Web page] Uppsala: The Human protein Atlas. STMN1 Stathmin. 2010-11-15 [updated 2001 Nov 15; cited 2010 Dec 20]. Available from:http://www.proteinatlas.org/ENSG00000117632.
23. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-9. (Pubitemid 30064988)
24. Engelsen IB, Stefansson I, Akslen LA, Salvesen HB. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 2006;195:979-86. (Pubitemid 44415644)
25. Kuo MF, Wang HS, Kuo QT, Shun CT, Hsu HC, Yang SH, et al. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 2009;4:74-80.
26. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006;94:717-23. (Pubitemid 43361904)
27. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, et al. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 2008;110:317-26.
28. Lin WC, Chen SC, Hu FC, Chueh SC, Pu YS, Yu HJ, et al. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009.
29. Wang X, Zhang H, Di W, Li W. Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma. Am J Obstet Gynecol 2009;201:194 e1-e10.
30. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:543 e1-7.
31. Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004;93:34-40. (Pubitemid 38429546)
32. Steinbakk A, Skaland I, Gudlaugsson E, Janssen EA, Kjellevold KH, Klos J, et al. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. Am J Obstet Gynecol 2009;200:78 e1-8.
33. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
34. Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 1993;71:3697-702.
35. Creasman WT, Morrow CP, BN Bundy, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.
36. Aalders JG, Thomas G. Endometrial cancer-revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol 2007;104:222-31. (Pubitemid 46054140)
37. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, et al. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 2004;199: 388-93. (Pubitemid 39120053)
38. Mariani A, Sebo TJ, Katzmann JA, Roche PC, Keeney GL, Lesnick TG, et al. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol 2005;96:594-600.
39. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
40. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
41. Ruzzo A, Graziano F, Canestrari E, Magnani M. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Curr Cancer Drug Targets 2010;10:68-79.
42. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22:2159-66. (Pubitemid 41095150)
43. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5 Suppl 6:S3-6.
44. Alli E, Yang J-M, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Molecular Pharmacology 2007;71:1233-40. (Pubitemid 46658676)
45. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Research 2005;65:10669-73. (Pubitemid 41713332)